Mark Breidenbach
Stock Analyst at Oppenheimer
(1.28)
# 3,706
Out of 5,124 analysts
52
Total ratings
30.91%
Success rate
-0.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.37 | +410.95% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $18.97 | +58.14% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $11.86 | +701.01% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.58 | +279.94% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.31 | +3,174.39% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $14.85 | +1,516.16% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.77 | +5,676.17% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.53 | +357.52% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.59 | +1,912.58% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.73 | +449.45% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.12 | +10,614.29% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.98 | +993,783.79% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.37
Upside: +410.95%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $18.97
Upside: +58.14%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $11.86
Upside: +701.01%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.58
Upside: +279.94%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.31
Upside: +3,174.39%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $14.85
Upside: +1,516.16%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.77
Upside: +5,676.17%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.53
Upside: +357.52%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.59
Upside: +1,912.58%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.73
Upside: +449.45%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.12
Upside: +10,614.29%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.98
Upside: +993,783.79%